Pemphigus: Navigating Trials and Treatment Innovations

The diagnostic odyssey

Pemphigus is a rare autoimmune blistering disorder characterized by the formation of painful blisters on the skin and mucous membranes. The diagnostic odyssey for patients with pemphigus can be particularly burdensome due to the rarity of the condition and the often vague initial symptoms. Many patients experience a prolonged journey of misdiagnoses before receiving the correct diagnosis, which can delay treatment and worsen disease outcomes. The complexity of pemphigus, including its subtypes like pemphigus vulgaris, complicates the identification of eligible patients for clinical trials, as awareness and understanding of the disease can vary significantly among healthcare providers.

The trial landscape right now

Currently, there are two clinical trials actively recruiting participants for pemphigus, spanning across 14 sites in two countries, namely the United States and Turkey. The trials include:

• NCT04422912: This Phase I/II study, titled "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)," is sponsored by Cabaletta Bio and is being conducted in the United States.
• NCT07384221: This study, titled "Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients," is sponsored by Saglik Bilimleri Universitesi in Turkey.

These trials reflect the ongoing efforts to explore new treatments and therapies for pemphigus, highlighting the need for innovative approaches in clinical research to recruit the right patient populations effectively.

How we detect the match

A significant advancement in improving patient recruitment for clinical trials lies in the integration of HL7 and FHIR standards with artificial intelligence (AI). By utilizing FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can automatically surface eligible patients without the need for extensive manual chart reviews. For instance, specific lab results or genetic markers related to pemphigus can be flagged through computable phenotypes.

This integration allows for real-time patient identification based on existing clinical data, ensuring that patients who meet the trial criteria are promptly informed of potential opportunities. By reducing the time spent on manual searches, healthcare providers can focus on delivering care while simultaneously enhancing trial recruitment efficiency.

Beyond the trial: better care

The benefits of integrating HL7/FHIR and AI extend beyond trial recruitment. This technology can significantly shorten the diagnostic odyssey for patients with pemphigus by streamlining the identification of relevant clinical data and improving care coordination. For instance, when a patient presents with symptoms suggestive of pemphigus, healthcare providers can quickly access their medical history, relevant lab results, and any previous diagnoses. This leads to more timely and accurate diagnoses, ultimately improving patient outcomes.

Moreover, enhanced monitoring and coordination of care can be achieved through the same integrated systems, whether or not the patient enrolls in a trial. Continuous data aggregation allows for better tracking of the disease's progression and response to treatments, which is crucial for managing a complex condition like pemphigus.

The takeaway

Pemphigus remains a challenging condition, both in terms of diagnosis and treatment. The ongoing clinical trials, such as those identified through NCT04422912 and NCT07384221, represent critical efforts to develop new therapies. Meanwhile, the integration of HL7, FHIR, and AI offers promising pathways to improve patient matching and care coordination, ultimately benefiting those affected by this rare disease.